SMN1 and systemic lupus erythematosus: Our results indicate that anti-SMN antibodies may serve as a useful biomarker for disease stratification, assessment of disease activity and organ involvement, and prediction of relapse and prognosis in patients with SLE, in addition to those with MCTD.